Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.
NCT ID: NCT01405872
Last Updated: 2014-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
270 participants
OBSERVATIONAL
2011-09-30
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Avonex PEN Satisfaction and Patients Experience Clinical Trial
NCT01366040
Canadian Avonex PEN Productivity Study
NCT01489748
Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen
NCT02076841
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance
NCT01156298
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
NCT00675883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AVONEX PEN
Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must satisfy the locally approved therapeutic indications for the Avonex PEN
* Decision to treat with Avonex PEN must precede enrollment
* Must have no more than two (2) injections with the Avonex PEN prior to enrollment
Exclusion Criteria
* Other unspecified reasons that, in the opinion of the investigator or Biogen Idec, make the patient unsuitable for enrollment
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Glostrup Municipality, , Denmark
Research Site
Holstebro, , Denmark
Research Site
Næstved, , Denmark
Research Site
Amiens, , France
Research Site
Clermont-Ferrand, , France
Research Site
Créteil, , France
Research Site
Nancy, , France
Research Site
Rouen, , France
Research Site
Strasbourg, , France
Research Site
Aachen, , Germany
Research Site
Bamberg, , Germany
Research Site
Berlin, , Germany
Research Site
Dresden, , Germany
Research Site
Eisenach, , Germany
Research Site
Erbach im Odenwald, , Germany
Research Site
Freiburg im Breisgau, , Germany
Research Site
Hamburg, , Germany
Research Site
Heidenheim, , Germany
Research Site
Herford, , Germany
Research Site
Itzehoe, , Germany
Research Site
Kastellaun, , Germany
Research Site
München, , Germany
Research Site
Nagold, , Germany
Research Site
Potsdam, , Germany
Research Site
Regensburg, , Germany
Research Site
Rottweil, , Germany
Research Site
Rüdersdorf, , Germany
Research Site
Schwendi, , Germany
Research Site
Siegen, , Germany
Research Site
Sinsheim, , Germany
Research Site
Stade, , Germany
Research Site
Weil am Rhein, , Germany
Research Site
Weisbaden, , Germany
Research Site
Wolfratshausen, , Germany
Research Site
's-Hertogenbosch, , Netherlands
Research Site
Eindhoven, , Netherlands
Research Site
Heerlen, , Netherlands
Research Site
Leeuwarden, , Netherlands
Research Site
Sittard, , Netherlands
Research Site
Bergen, , Norway
Research Site
Drammem, , Norway
Research Site
Førde, , Norway
Research Site
Molde, , Norway
Research Site
Tønsberg, , Norway
Research Site
Amadora, , Portugal
Research Site
Košice, , Slovakia
Research Site
Helsingborg, , Sweden
Research Site
Karlstad, , Sweden
Research Site
Linköping, , Sweden
Research Site
Norrköping, , Sweden
Research Site
Skövde, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Trollhättan, , Sweden
Research Site
Lucerne, , Switzerland
Research Site
Lugano, , Switzerland
Research Site
Sankt Gallen, , Switzerland
Research Site
Sion, , Switzerland
Research Site
Dundee, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
Hammersmith, , United Kingdom
Research Site
Haywards Heath, , United Kingdom
Research Site
Irvine, , United Kingdom
Research Site
Leicester, , United Kingdom
Research Site
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hupperts R, Becker V, Friedrich J, Gobbi C, Salgado AV, Sperling B, You X. Multiple sclerosis patients treated with intramuscular IFN-beta-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv. 2015 Jan;12(1):15-25. doi: 10.1517/17425247.2015.989209. Epub 2014 Nov 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
108MS402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.